Table 1.
Clinical inputs parameter estimates
| Parameter | Annual probabilities | |||
|---|---|---|---|---|
| Non-prophylaxis | Source | Palivizumab | Source | |
| Probability of hospital admission due RSV infection | ||||
| Total population | 4.10% | [14] | 1.30% | [14] |
| Subgroup A | 18.40% | [33] | 9.50% | [33] |
| Subgroup B | 10.60% | 3.60% | ||
| Subgroup C | 10.20% | 2.90% | ||
| Probability of emergency visits prior to hospital admission | ||||
| 17.80% | [14] | 17.80% | [14] | |
| Probability of death related to hospital admission | ||||
| 2.33% | [3] | 2.33% | [3] | |
| Probability of additional hospitalizations due to new RSV infection | ||||
| 2.47% | [14] | 2.47% | [14] | |
| Probability of recurrent wheezing in hospitalized patients. | ||||
| Year 2 | 41.43% | [15] | 18.43% | [15] |
| Year 3 | 29.27% | 11.05% | ||
| Year 4 | 18.55% | 6.12% | ||
| Year 5 | 15.00% | 4.39% | ||
| Year 6 | 12.39% | 3.25% | ||
| Probability of recurrent wheeze in no-hospitalized patients | ||||
| Year 2 | 12.09% | [15] | 5.38% | [15] |
| Year 3 | 15.36% | 5.80% | ||
| Year 4 | 12.57% | 4.15% | ||
| Year 5 | 9.31% | 2.73% | ||
| Year 6 | 9.66% | 2.53% | ||
Subgroup A includes preterm infants with 2 major risk factors and 2 minor risk factors; subgroup B, 2 major risk factors and 1 minor risk factors; subgroup C, 2 major risk factors [33]
Major factors: chronological age less than 10 weeks at the beginning of RSV season or being born during the first 10 weeks of the season; school-age siblings or day-care attendance. Minor factors: mother smoking during pregnancy and male gender